Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555)

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Rahbari, Nuh N ^a   Lordick, Florian ^b   Fink, Christine ^a   Bork, Ulrich ^a   Stange, Annika ^a   Jäger, Dirk ^a   Luntz, Steffen P ^c   Englert, Stefan ^a   Rossion, Inga ^a   Koch, Moritz ^a   Büchler, Markus W ^a   Kieser, Meinhard ^a   Weitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; COLON CANCER; COLON RESECTION; HEMICOLECTOMY; METASTASIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); CANCER STAGING; CARCINOMA; CLINICAL TRIAL; COLON TUMOR; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; METHODOLOGY; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CARCINOMA; COLONIC NEOPLASMS; COLORECTAL SURGERY; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84859326703     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-142     Document Type: Article

References (26)

1. Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 1997, 84(12):1731-1736. 10.1002/bjs.1800841224, 9448628.
2. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005, 23(28):7125-7134. 10.1200/JCO.2005.08.722, 16192596.
3. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8(4):347-353. 10.1007/s10434-001-0347-3, 11352309.
4. Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, Millis JM, Posner MC. Initial presentation with stage IV colorectal cancer: how aggressive should we be?. Arch Surg 2000, 135(5):530-534. 10.1001/archsurg.135.5.530, 10807276.
5. Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 2008, 23(6):559-568. 10.1007/s00384-008-0456-6, 18330581.
6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345(23):1655-1659. 10.1056/NEJMoa003013, 11759643.
7. Mickisch GH, Garin A, van PH, de PL, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358(9286):966-970. 10.1016/S0140-6736(01)06103-7, 11583750.
8. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24(18):2743-2749. %20, 10.1200/JCO.2005.04.2226, 16702580.
9. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008, 247(5):732-738. 10.1097/SLA.0b013e3181656d32, 18438108.
10. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008, 19(11):1829-1835. 10.1093/annonc/mdn398, 18662955.
11. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370(9582):143-152. 10.1016/S0140-6736(07)61087-3, 17630037.
12. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-4786. %20, 10.1200/JCO.2007.11.3357, 17947725.
13. Saltz LB, Clarke S, az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. %20, 10.1200/JCO.2007.14.9930, 18421054.
14. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 2003, 196(5):722-728. 10.1016/S1072-7515(03)00136-4, 12742204.
15. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, Livingston S, Andreyev J. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003, 52(4):568-573. 10.1136/gut.52.4.568, 1773619, 12631671.
16. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005, 12(8):637-645. 10.1245/ASO.2005.06.012, 15965730.
17. Kleespies A, Fuessl KE, Seeliger H, Eichhorn ME, Muller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW. Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis 2009, 24(9):1097-1109. 10.1007/s00384-009-0734-y, 19495779.
18. Costi R, Mazzeo A, Di MD, Veronesi L, Sansebastiano G, Violi V, Roncoroni L, Sarli L. Palliative resection of colorectal cancer: does it prolong survival?. Ann Surg Oncol 2007, 14(9):2567-2576. 10.1245/s10434-007-9444-2, 17541693.
19. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001, 93(8):583-596. 10.1093/jnci/93.8.583, 11309435.
20. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, et al. Update S3-guideline "colorectal cancer" 2008. Z Gastroenterol 2008, 46(8):799-840. 10.1055/s-2008-1027726, 18759205.
21. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006, 94(6):798-805. 10.1038/sj.bjc.6603011, 2361370, 16508637.
22. Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, Holm T, Wong WD, Tiret E, Moriya Y, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 2010, 147(3):339-351. 10.1016/j.surg.2009.10.012, 20004450.
23. Van CE, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417. 10.1056/NEJMoa0805019, 19339720.
24. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982, 1(2):121-129. 10.1002/sim.4780010204, 7187087.
25. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. JASA 1989, 84:1074-1078.
26. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010, 375(9719):1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.